Tissue Regenix : Final results presentation for the year ended 31 December 2023

Building a Leading Regenerative Medicines Business

Final results for the year ended 31 December 2023

March 2024

Disclaimer

This presentation, which has been prepared by, and is the sole responsibility of, Tissue Regenix Group plc (the "Company"), has been prepared solely in connection with the Company's Annual financial results for the 12 month period ended 31st December 2023. For the purposes of this notice, this "Presentation" shall mean the slides that follow, any oral presentation of the slides by the Company or any person on its behalf, any question-and answer session that follows any oral presentation, hard copies of this document and any materials distributed in connection with this Presentation. This Presentation, its contents and any information provided or discussed in connection with it are strictly private and confidential and may not be reproduced, redistributed or transmitted, directly or indirectly, to any other person or published, in whole or in part, for any purpose, without the prior written consent of the Company (provided that you may disclose this Presentation on a confidential basis to your legal, tax or investment advisers (if any) for the purposes of obtaining advice).

This Presentation is for information purposes only and does not constitute or form part of any offer or invitation to sell or issue or any solicitation of any offer to purchase or subscribe for any shares or other securities of the Company in any jurisdiction nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied upon in connection with or act as any inducement to enter into, any contract or commitment whatsoever. This Presentation is not a recommendation regarding the securities of the Company or the basis of any investment decision. Recipients should therefore not purchase, subscribe for or otherwise acquire any securities of the Company on the basis of this Presentation.

This Presentation does not purport to be a complete description of the Company's business or results. No undertaking, representation, warranty or other assurance, express or implied, is made or given by or on behalf of the Company nor any of its directors, officers, employees, agents, affiliates, representatives or advisers or any other person as to the accuracy or completeness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any of them for any such information or opinions.

The information contained in this Presentation is provided as at the date of its publication. This Presentation contains statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements may involve substantial risks and uncertainties and actual results and developments may differ materially from those expressed or implied by these statements by a variety of factors. Forward-looking statements are sometimes identified by the use of forward-looking terminology such as "believe", "expects", "may", "will", "could", "should", "shall", "risk", "intends", "estimates", "aims", "plans", "predicts", "continues", "assumes", "positioned" or "anticipates" or the negative thereof, other variations thereon or comparable terminology. These forward-looking statements speak only as at the date of this Presentation.In addition, all projections, valuations and statistical analyses provided in this Presentation may be based on subjective assessments and assumptions and may use among alternative methodologies that produce different results and should not be relied upon as an accurate prediction of future performance. Except as required by applicable law or regulation, neither the Company nor any of its directors, officers, employees, agents, affiliates, representatives or advisers undertakes or agrees any obligation to update or revise any forward-looking or other statements or information in this Presentation, whether as a result of new information, future developments or otherwise. No statement in this Presentation is intended as a profit forecast or profit estimate (unless otherwise stated).

Where applicable, any industry, market and competitive position data contained in this Presentation has come from official or third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data and the Company has not independently verified the data contained therein. Certain of the industry, market and competitive position data contained in this Presentation comes from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Further, the Company's competitors may define the Company's and their markets differently than the Company does. Accordingly, undue reliance should not be placed on any of the industry, market and competitive position data contained in this presentation.

Past performance is not indicative of future results. The value of investments may fall as well as rise and investors may not get back the amount invested. Changes in rates of foreign exchange may cause the value of investments to go up or down.

No representation is being made that any investment will or is likely to achieve profits or losses similar to those achieved in the past, or that significant losses will be avoided. This Presentation is intended for distribution to persons in the United Kingdom who have professional experience in matters relating to investments, who are investment professionals, high net worth companies, high net worth unincorporated associations or partnerships or trustees of high value trusts, and investment personnel of any of the foregoing (each within the meaning of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005).

By attending or receiving this Presentation (whether in hard copy form or electronically), you irrevocably represent, warrant and undertake to the Company that you have read, understood and agree to comply with, and be bound by, the terms

of this notice and you acknowledge that you understand the legal and regulatory sanctions attached to the misuse or improper disclosure or distribution of this Presentation.	2

Presenters

DANIEL LEE	DAVID COCKE
Chief Executive Officer	Chief Financial Officer
Joined Jan 2019, appointed to CEO in Nov 2020	Joined Jan 2021
• Over 30 years' experience in medical device and biologics	• Over 30 years' experience in the medical device industry
• Former President of US Operations at CellRight Technologies	• Founding partner of NuPak Medical, contract manufacturer of
and Former CEO of Scaffold Biologics and Aperion Biologics	sterile disposable medical devices, former CFO at Aperion Biologics
	(2008-2017) and experience at Salomon Brothers and GE Capital

• B.E.S in Materials Science and Engineering from the Johns Hopkins University and M.S. in Biomedical Engineering from the University of Alabama

• B.B.A. in Business Honors from the University of Texas at Austin and M.B.A. from the University of Virginia

3

Company Overview

Pioneering medical technology company in the field of regenerative medicine

dCELL® & BioRinse®- two platform technologies utilising bone and soft

tissues for the treatment of numerous surgical and non-surgical indications

International manufacturing capabilities - US, UK & Germany

Extensive and expanding product portfolio

Strategic partnerships with industry leaders and market distributors

Multi-billion-dollar addressable market, transforming patient care and delivering favourable health economic outcomes

4

4

2023 Highlights

Financial Highlights

Group revenues increased by 20% to $29.5m (2022: $24.5m)

Gross profit for the year increased to 48% (2022: 46%)

Adjusted EBITDA profit of $925k against an adjusted EBITDA loss of $626k in 2022

The cash position as at 31 Dec 2023 of $4.7m (31 Dec 2022: $5.9m)

• Cash position increased in the H2 2023

Divisional Revenue Highlights

To $20.1m (2022: $16.0m)

25% result of continued and increased demand for the diversified product portfolio with existing and new customers

17%	To $6.2m (2022: $5.3m)
due to the increased commercial activity

5

2023 Highlights

2023 Commercial and Operational Highlights

28% year-on-year increase in donor processing throughput during 2023, as a result of additional efficiencies realized from the Phase 1 capacity expansion

Addition of new BioRinse® product line for all sports medicine allografts and dCell® product line extensions for DermaPure® Mesh and VNEW

Regulatory approval of logistics partner for allograft distribution in the EU and signing of distribution partner in Spain

Distribution agreements for OrthoPure® XT in the UK, China and Australia

"4S" Strategy continues to drive the Group's strategy: Supply, Sales Revenue, Sustainability and Scale

6

6

Core Product Portfolio and Line Extensions

High Growth Product Lines Focused On Bone, Soft and Birth Tissues

Processing						dCELL®
Platform		(bone and birth tissue)		(soft tissue)
By revenue		$20.1m in 2023		$6.2m in 2023
(USD)
Flagship / high		ConCelltrate®		AmnioWorksTM		DermaPure®
growth Products
New product	•	Expansion of private label opportunities	•	Expansion of private label opportunities	•	DermaPure® Mesh 4 x 6
line extensions	•	Sports medicine grafts	•	VNEW® M
	•	Foot / Ankle			•	Wound care
			•	Hernia
	•	Spine	•	Ophthalmology
Applications	•	Plastic surgery
•	Dental	•	Wound care
	•	Urogynaecology
	•	Orthopaedics
			•	Sports medicine
	✓ 100% Demineralized Bone Matrix	✓	Aesthetics	✓	Take - 99% DNA removal
	✓	Sterile	✓	Integration
Differentiators	✓	Clinical outcomes
✓	Each lot verified for osteoinductivity	✓	Handling
	✓	Stored at room temperature	7
	✓	Handling and use properties	✓	Stored at room temperature

Product Highlights

Annual	2019	2020	2021	2022	2023
Growth
BioRinse	+1%	+11%	+33%	+26%	+25%
dCELL	+20%	-21%	+0%	+25%	+17%
GBM-V	+6%	+1%	+5%	+12%	+2%

BioRinse- Strong sales growth in US market

• BioRinse US - exceptionally strong performance 25% growth from 2022
• Indicative of the continued confidence in our products
• Strong performance of distributors and strategic partners

dCELL - US reorganisation continues to reinvigorate sales growth

• Commercial reorganisation shows results-salesup 17% for 2023
• OrthoPure XT - market expansion of the only commercially available xenograft for sports medicine indications

8

New Product Line Launches

	DermaPure®				VNEW® M
	Mesh 4 x 6		Sports Medicine
			Soft Tissue

Product line extension and smaller version of product introduced in 2021

Meshed 3:1 is designed for greater

New processing protocols designed to minimize processing effects to produce sterile soft tissue products

Alternative precut dermal graft designed to facilitate pelvic organ prolapse (POP) repair procedures

surface area coverage	Meets market expectations and
	enables us to be more competitive

Products requested by the market demand and our strategic partners will enable to us to continue to enhance our

growth potential in the near term

9

Multi-Billion-Dollar Addressable Market

Global Bone Graft Substitutes market projected to grow at 6.1% CAGR to c. $6.0 billion by 2029

• Increase in prevalence of spinal fusion or other chronic diseases and trauma emergencies
• Market demand and growth returning to pre-pandemic levels
• Rise in awareness related to tissue engineering in global markets
• Key competitors include MTF, LifeNet, RTI Surgical, CTS, AlloSource and XTANT

DBM

U.S. Skin Substitute market projected to grow at 2.2% CAGR to c. $2.0 billion by 2028

• Focus areas are wound management, sports related injuries and uro-gynaecology

(through partnership with ARMS Medical)

• Key competitors include Integra, Organogenesis, MiMedx and ColoPlast

	Types of	Allograft
Synthetic	Bone Graft	inc.
	Substitutes	cellular

Xenograft

Global Soft Tissue Biologics market projected to grow at 5.0% CAGR to $3.9 billion by 2028

• Focus area is ligament repair
• Key competitors are MTF, LifeNet, RTI Surgical, CTS, AlloSource and Corin Group

Growing faster than the markets we compete in due to superior product performance, responsive customer service and

adaptability to client needs

Source: GRc Consulting

1 - https://reports.valuates.com/market-reports/ALLI-Auto-1B403/tissue-engineering

10 10